Table 1.
Patient Demographics (N=5,964)
| Characteristic | Surgical Volume |
P | ||
|---|---|---|---|---|
| High (n=1,653) | Mid (n=3,662) | Low (n=649) | ||
|
| ||||
| Age (y) | 47.2±11.7 | 48.0±12.0 | 49.5±12.1 | <.001 |
| Year | <.001 | |||
| 2004 | 352 (21.3) | 581 (15.9) | 132 (20.3) | |
| 2005 | 323 (19.5) | 751 (20.5) | 103 (15.9) | |
| 2006 | 329 (19.9) | 751 (20.5) | 114 (17.6) | |
| 2007 | 327 (19.8) | 835 (22.8) | 137 (21.1) | |
| 2008 | 322 (19.5) | 744 (20.3) | 163 (25.1) | |
| Clinical stage | .003 | |||
| IB1 | 931 (56.3) | 1,906 (52.0) | 348 (53.6) | |
| IB2 | 270 (16.3) | 544 (14.9) | 86 (13.3) | |
| IIA | 141 (8.5) | 390 (10.6) | 72 (11.1) | |
| IIB | 311 (18.8) | 822 (22.4) | 143 (22.0) | |
| Histology | .064 | |||
| Squamous | 1,070 (64.7) | 2,382 (65.0) | 448 (69.0) | |
| Adenocarcinoma | 399 (24.1) | 943 (25.8) | 147 (22.7) | |
| Adenosquamous | 163 (9.9) | 289 (7.9) | 44 (6.8) | |
| Others | 21 (1.3) | 48 (1.3) | 10 (1.5) | |
| Parametrial involvement | .521 | |||
| No | 1,320 (79.9) | 2,970 (81.1) | 527 (81.2) | |
| Yes | 333 (20.1) | 690 (18.9) | 122 (18.8) | |
| Node metastasis (pelvic) | .122 | |||
| No | 1,191 (72.4) | 2,723 (74.9) | 469 (72.9) | |
| Yes | 454 (27.6) | 911 (25.1) | 174 (27.1) | |
| Node metastasis (para-aortic) | .004 | |||
| No | 218 (14.2) | 552 (16.0) | 67 (10.7) | |
| Yes | 39 (2.5) | 71 (2.1) | 10 (1.6) | |
| Not examined* | 1,283 (83.3) | 2,829 (82.0) | 551 (87.7) | |
| Sampled lymph nodes | <.001 | |||
| Pelvic | 42 (32–53) | 35 (26–47) | 40 (28–52) | |
| Para-aortic | 9 (5–15) | 8 (3–14) | 6 (4–12) | .036 |
| Deep stromal invasion | .001 | |||
| No | 621 (43.0) | 1,708 (48.7) | 307 (48.3) | |
| Yes | 822 (57.0) | 1,801 (51.3) | 329 (51.7) | |
| Tumor size (cm) | .809 | |||
| 4 or less | 1,056 (70.0) | 2,377 (69.4) | 421 (68.9) | |
| More than 4 | 453 (30.0) | 1,047 (30.6) | 193 (31.4) | |
| LVSI | .020 | |||
| No | 676 (42.4) | 1,662 (46.6) | 275 (44.4) | |
| Yes | 918 (57.6) | 1,907 (53.4) | 344 (55.6) | <.001 |
| Uterine corpus invasion | ||||
| No | 1,305 (83.4) | 3,157 (87.3) | 561 (87.9) | |
| Yes | 260 (16.6) | 459 (12.7) | 77 (12.1) | |
| Ovarian metastasis | .735 | |||
| No | 1,469 (98.6) | 3,538 (98.9) | 620 (98.7) | |
| Yes | 21 (1.4) | 41 (1.1) | 8 (1.3) | |
| Peritoneal cytology | <.001 | |||
| No malignant cells | 463 (28.0) | 748 (20.5) | 146 (22.5) | |
| Malignant cells | 33 (2.0) | 55 (1.5) | 2 (0.3) | |
| Not examined* | 1,157 (70.0) | 2,837 (77.9) | 501 (77.2) | |
| Neoadjuvant chemotherapy | .002 | |||
| No | 1,356 (83.1) | 2,998 (82.4) | 500 (77.2) | |
| Yes | 275 (16.9) | 639 (17.6) | 148 (22.8) | |
| Adjuvant therapy | .003 | |||
| None | 678 (41.7) | 1,313 (37.1) | 253 (39.7) | |
| Radiotherapy alone | 295 (18.2) | 642 (18.2) | 101 (15.9) | |
| CCRT | 341 (21.0) | 830 (23.5) | 136 (21.4) | |
| Chemotherapy alone | 302 (18.6) | 697 (19.7) | 140 (22.0) | |
| Combined† | 9 (0.6) | 54 (1.5) | 7 (1.1) | |
LVSI, lymphovascular space invasion; and CCRT, concurrent chemoradiotherapy.
Data are mean±SD, n (% per column), or median (interquartile range) unless otherwise specified.
One-way analysis of variance test, Kruskal-Wallis test, or χ2 test was used for P-values.
Bold indicates significant P-value.
Total number may not be 5,964 owing to missing data.
*
Histologically assessed.
†
Both systemic chemotherapy and radiotherapy.